News
TLPH
0.8853
+1.36%
0.0119
Weekly Report: what happened at TLPH last week (0608-0612)?
Weekly Report · 16h ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 06/08 17:06
Weekly Report: what happened at TLPH last week (0601-0605)?
Weekly Report · 06/08 09:06
Dollar Tree, Onto, Chipotle, Lululemon, Talphera Trending
TipRanks · 06/06 09:01
Talphera Price Target Announced at $3.00/Share by HC Wainwright & Co.
Dow Jones · 06/05 12:51
Talphera Coverage Assumed by HC Wainwright & Co. at Buy
Dow Jones · 06/05 12:51
HC Wainwright & Co. Assumes Talphera at Buy, Announces Price Target of $3
Benzinga · 06/05 12:42
Talphera assumed with a Buy at H.C. Wainwright
TipRanks · 06/05 10:27
Weekly Report: what happened at TLPH last week (0525-0529)?
Weekly Report · 06/01 09:06
Weekly Report: what happened at TLPH last week (0518-0522)?
Weekly Report · 05/25 09:07
Talphera Earnings Call Highlights NEPHRO Trial Momentum
TipRanks · 05/20 00:27
Talphera Reports Q1 Loss Of $2 Mln; Completes 50% Enrolment In Phase 3 Trial
NASDAQ · 05/19 16:14
Weekly Report: what happened at TLPH last week (0511-0515)?
Weekly Report · 05/18 09:06
Talphera Earnings Call Highlights Trial Momentum, Risks
TipRanks · 05/15 00:29
CorMedix Q1 net income rises to $38.6 million; revenue more than doubled to $127.4 million
PUBT · 05/14 12:01
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 05/14 11:42
Talphera targets Niyad PMA filing in 2026 and potential approval in 2027 as NEPHRO enrollment surpasses 50%
Seeking Alpha · 05/13 23:21
Talphera Q1 2026 Earnings Call Transcript
Benzinga · 05/13 21:40
Talphera reports Q1 EPS (4c) vs. (10c) last year
TipRanks · 05/13 21:03
Talphera Q1 net loss narrows as costs rise on higher development spending
Reuters · 05/13 20:18
More
Webull provides a variety of real-time TLPH stock news. You can receive the latest news about Talphera Inc through multiple platforms. This information may help you make smarter investment decisions.
About TLPH
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.